References
- KirchhofPBenussiSKotechaD2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J201637382893296227567408
- KirchhofPBenussiSKotechaD2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J201637382893296227567408
- KryukovAVSychevDAAndreevDAThe pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phaseRation Pharmacother Cardiol2016123253259
- ELIQUIS® (apixaban) [prescribing information] Princeton, NJBristol-Myers Squibb Company2017
- XARELTO® (rivaroxaban) [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc.2014
- SAVAYSA (edoxaban) [prescribing information]TokyoDaiichi Sankyo Co., LTD.2015
- DimatteoCD’AndreaGVecchioneGABCB1 SNP rs4148738 modulation of apixaban interindividual variabilityThromb Res2016145242627434880
- Ing LorenziniKDaaliYFontanaPDesmeulesJSamerCRivaroxaban-induced hemorrhage associated with ABCB1 genetic defectFront Pharmacol2016749428066243
- VandellAGLeeJShiMRubetsIBrownKSWalkerJRAn integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposurePharmacogenomics J201618115315927897269
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for Industry, Statistical Approaches to Establishing BioequivalenceSilver Spring, MDUS Food and Drug Administration2001 Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm070244Accessed March 8, 2018
- European Medicines AgencyGuideline on the Investigation of BioequivalenceLondonEMEA2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdfAccessed March 8, 2018
- Gouin-ThibaultIDelavenneXBlanchardAInter-individual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycinJ Thromb Haemost2016152273283
- ChanSWXiaoYHuMAssociations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6 b-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male ChineseJ Clin Pharm Ther201641555255827511886
- DutreixCLorenzoSWangYComparison of two endogenous biomarkers of CYP3A4 activity in a drug – drug interaction study between midostaurin and rifampicinEur J Clin Pharmacol201470891592024839948
- EldesokyESKamelSIFarghalyAMBakheetMYHedayaMASiestJ-PStudy of the urinary ratio of 6 beta-hydroxycortisol/cortisol as a biomarker of CYP3A4 activity in Egyptian patients with chronic liver diseasesBiomark Insights2007115716419690646
- KawaguchiAOhmoriMTsuruokaSDrug interaction between St John’s Wort and quazepamBr J Clin Pharmacol200458440341015373933
- KonishiHTanakaKMinouchiTYamajiAUrinary 6beta-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme inductionAnn Clin Biochem200441pt 433533715298747
- ZhengWJinFDunningLAEpidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer riskCancer Epidemiol Biomarkers Prev200110323724211303593
- Ministry of Health and Social Development of Russian FederationGuidelines for the Evaluation of Bioequivalence of MedicinesMoscowMinistry of Health and Social Development of Russian Federation2008 Available from: http://dissolutiontech.ru/assets/files/be-2008.pdfAccessed March 12, 2018 Russian